PR97688

LISBON, Portugal, September 6, 2022 /PRNewswire=KYODO JBN/--

Hovione, the leader in spray drying and particle engineering, announced today

that it has expanded its continuous manufacturing offering and services. A new

state-of-the-art continuous manufacturing facility is now coming online at the

Loures site in Portugal. In addition, to support Hovione's commitment to

providing access and services for continuous tableting, Hovione has further

strengthened its capabilities by establishing a highly experienced

multi-disciplinary global team in continuous tableting and upgrading its labs

with the tools needed to support the drug product lifecycle, thereby further

guaranteeing competency and capacity from research & development to production.

Continuous manufacturing is expected to change the landscape of drug product

development and commercial production. The Food and Drug Administration (FDA)

is partnering with the International Council for Harmonization and leading a

global initiative to advance continuous manufacturing of small molecules and

other pharmaceutical modalities.

Hovione is offering customers a commercial continuous tableting platform

prepared to support key control needs and deliver on operational excellence,

mechanistic modeling, and appropriate process analytical technology (PAT).

Additionally, Hovione´s quality system has been designed to support the release

of continuous tableting products through automated in-process controls,

deployment of real time release, and compliant digital infrastructure.

This cutting-edge technology offers a distinct set of features and advantages

including faster development of simpler processes, agile manufacturing for

variable demand, robust control strategies and high process quality standards.

"Hovione has been historically focused on innovative technologies that benefit

our customers and patients. With this investment in continuous tableting, our

customers can rely on our support to bring much needed medicines to the market

as fast as possible with the highest quality and manufacturing standards.",

comments Jean-Luc Herbeaux, Hovione´s CEO. "We are investing to accelerate the

adoption of this technology as we continue to innovate and enhance our offering

around our areas of expertise."

"This investment in continuous tableting from R&D to production further

strengthens Hovione´s CDMO offering and responds to the growing customer

interest." says Filipe Neves, Hovione´s Strategic Business Director.

This latest investment in Continuous Tableting is part of Hovione´s broader

strategy to build differentiated and enabling capabilities and assets to meet

customers unique needs for oral dosage forms manufacturing.

About Hovione

Hovione is an international company with over 60 years of experience as a

Contract Development and Manufacturing Organization (CDMO) with a fully

integrated offering of services for drug substance, drug product intermediate

and drug product. The company has four FDA inspected sites in the USA,

Portugal, Ireland and China and development laboratories in Lisbon, Portugal

and New Jersey, USA. Hovione provides pharmaceutical customers services for the

development and compliant manufacture of innovative drugs, including highly

potent compounds, and customized product solutions across the entire drug life

cycle. In the inhalation area, Hovione offers a complete range of services,

from API and formulation development to devices. Hovione´s culture is based on

innovation, quality and delivery. Hovione was the first Chemical/

Pharmaceutical Company to become a Certified B Corp, is a member of Rx-360,

EFCG and participates actively in industry quality improvement initiatives to

lead new global industry standards.

For more information, please visit www.hovione.com　

Photo - https://mma.prnewswire.com/media/1892354/Hovione_Tableting_equipment.jpg

Photo - https://mma.prnewswire.com/media/1892355/Hovione_Campaign_Mood.jpg

Logo - https://mma.prnewswire.com/media/1686008/Logo_Hovione_Logo.jpg

SOURCE: Hovione